Screener
KYN
Kyntra Bio
KYNBKyntra Bio is a biopharmaceutical company specializing in the development of novel therapies for cancer and anemia.
$30.81M+1.6%
Earnings
Next report
Nov 9, 2026 (in 2 months)Revenue estimate$1.8M
EPS estimate-$3.66
Competitors
By market cap
By revenue growth
Profile
Kyntra Bio is a biopharmaceutical company specializing in the development of novel therapies for cancer and anemia. The company focuses on advancing antibody-drug conjugates for oncology and small molecule inhibitors for rare disease indications. Its core value proposition lies in addressing high unmet medical needs through first-in-class treatments and companion diagnostic biomarkers.
Competitive position
Kyntra Bio is a clinical-stage developer in oncology while maintaining a commercial-stage presence in anemia through global licensing partnerships.
GeographiesUnited States, Europe, Japan, Canada, Mexico
Customer segmentsHealthcare Providers, Pharmaceutical Companies
Business modelR&D, Licensing, IP Monetization
SuppliersContract Manufacturing Organizations (CMOs), Academic Research Institutions, Raw Material Suppliers
CustomersPharmaceutical Distributors, Hospitals, Specialty Pharmacies, Collaboration Partners
CountryUnited States of America
Listed2014
CEOThane Wettig
SectorHealthcare
IndustryMedical - Pharmaceuticals
Websitekyntrabio.com
FilingsSEC EDGAR
FAQ
- What is Kyntra Bio's market cap?
- Kyntra Bio (KYNB) has a market capitalization of $30.8M and trades on NASDAQ.
- Who are Kyntra Bio's competitors?
- Kyntra Bio's key competitors include Bristol Myers Squibb, Geron Corporation, Akebia Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does Kyntra Bio partner with?
- Kyntra Bio's notable partners include Astellas Pharma Inc., AstraZeneca, Fortis Therapeutics, Inc., and others.
- What subsidiaries does Kyntra Bio have?
- Kyntra Bio's subsidiaries include FibroGen International (Hong Kong) Ltd..
- Where is Kyntra Bio headquartered?
- Kyntra Bio is headquartered in United States of America. It has been publicly traded since 2014.